These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30590005)

  • 21. Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.
    Smith JJ; Wasserman I; Milgrom SA; Chow OS; Chen CT; Patil S; Goodman KA; Garcia-Aguilar J
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):924-930. PubMed ID: 28333014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms of Mismatch Repair Pathway Genes Predict Clinical Outcomes in Oral Squamous Cell Carcinoma Patients Receiving Adjuvant Concurrent Chemoradiotherapy.
    Senghore T; Wang WC; Chien HT; Chen YX; Young CK; Huang SF; Yeh CC
    Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31035658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Msh2 separation of function mutations confer defects in the initiation steps of mismatch repair.
    Kijas AW; Studamire B; Alani E
    J Mol Biol; 2003 Aug; 331(1):123-38. PubMed ID: 12875840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
    Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
    Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Polymorphism of Mismatch Repair Genes and Susceptibility to Prostate Cancer.
    Khooshemehri P; Jamaldini SH; Ziaee SAM; Afshari M; Sattari M; Narouie B; Sotoudeh M; Montazeri V; Sarhangi N; Hasanzad M
    Urol J; 2020 May; 17(3):271-275. PubMed ID: 31953835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meiotic arrest and aneuploidy in MLH3-deficient mice.
    Lipkin SM; Moens PB; Wang V; Lenzi M; Shanmugarajah D; Gilgeous A; Thomas J; Cheng J; Touchman JW; Green ED; Schwartzberg P; Collins FS; Cohen PE
    Nat Genet; 2002 Aug; 31(4):385-90. PubMed ID: 12091911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common germline variation in mismatch repair genes and survival after a diagnosis of colorectal cancer.
    Koessler T; Azzato EM; Perkins B; Macinnis RJ; Greenberg D; Easton DF; Pharoah PD
    Int J Cancer; 2009 Apr; 124(8):1887-91. PubMed ID: 19115210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defects of DNA mismatch repair in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
    Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy.
    Zhao C; Li S; Zhao M; Zhu H; Zhu X
    Arch Gynecol Obstet; 2018 Jan; 297(1):153-159. PubMed ID: 29063235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis.
    Sameer AS; Nissar S; Fatima K
    Eur J Cancer Prev; 2014 Jul; 23(4):246-57. PubMed ID: 24614649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers.
    Lipkin SM; Wang V; Stoler DL; Anderson GR; Kirsch I; Hadley D; Lynch HT; Collins FS
    Hum Mutat; 2001 May; 17(5):389-96. PubMed ID: 11317354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common variants in mismatch repair genes and risk of colorectal cancer.
    Koessler T; Oestergaard MZ; Song H; Tyrer J; Perkins B; Dunning AM; Easton DF; Pharoah PD
    Gut; 2008 Aug; 57(8):1097-101. PubMed ID: 18364438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
    Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
    Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms.
    Yuan ZQ; Gottlieb B; Beitel LK; Wong N; Gordon PH; Wang Q; Puisieux A; Foulkes WD; Trifiro M
    Hum Mutat; 2002 Feb; 19(2):108-13. PubMed ID: 11793469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair.
    Prolla TA; Baker SM; Harris AC; Tsao JL; Yao X; Bronner CE; Zheng B; Gordon M; Reneker J; Arnheim N; Shibata D; Bradley A; Liskay RM
    Nat Genet; 1998 Mar; 18(3):276-9. PubMed ID: 9500552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.